Likelihood of Approval and Phase Transition Success Rate Model – (Iparomlimab + Tuvonralimab) in Triple-Negative Breast Cancer (TNBC)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – (Iparomlimab + Tuvonralimab) in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


(Iparomlimab + Tuvonralimab) in Triple-Negative Breast Cancer (TNBC) Drug Details:
Iparomlimab and Tuvonralimab (Qibeian) is a bifunctional combination antibody, acts as an anti-neoplastic agent. It is formulated as a solution for intravenous route of administration. Qibeian is indicated for the treatment of patients with recurrent or metastatic cervical cancer who have failed previous platinum-containing chemotherapy.Tuvonralimab (PSB-205) in combination with iparomlimab is under development for the treatment of relapsed/refractory malignant solid tumors including squamous and non-squamous non-small cell lung cancer (NSCLC), recurrent or metastatic cervical cancer, nasopharyngeal carcinoma, head and neck squamous cell carcinoma (HNSCC), recurrent or metastatic endometrial cancer, hepatocellular carcinoma, locally advanced or metastatic gastric or gastroesophageal carcinoma, colon carcinoma, triple negative breast cancer, HER2 negative breast cancer, small cell lung cancer, kidney cancer (renal cell cancer), liver cancer, endometrial cancer, transitional cell cancer (urothelial cell cancer), advanced urothelial cancer, metastatic colorectal cancer, metastatic melanoma, soft tissue sarcoma, bone sarcoma, metastatic renal cell carcinoma. The drug candidate is a bi-specific antibody product that contains a mixture of unique anti-PD-1 and anti-CTLA4 monoclonal antibodies produced by a single cell line via the company’s proprietary MabPair technology. It is administered through intravenous drip and subcutaneous route. It is being developed based on MabPair antibody technology platform.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – (Iparomlimab + Tuvonralimab) LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports